Skip to main content
Clinical Trials/CTRI/2019/02/017549
CTRI/2019/02/017549Completed未知

CB-NAAT, Its clinical utility in diagnosing cases of cutaneous tuberculosis and assessing rifampicin resistance.

King Georges Medical University0 sites44 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
44

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • (a) Patients clinically diagnosed as cutaneous TB and who give consent to participate in

Exclusion Criteria

  • (a) Who have taken ATT in last one year
  • (b) Contra-indication for biopsy or FNAC like bleeding and clotting disorders
  • (c) Patients with severe debilitating and chronic illness like Hepatitis B,C, malignancy,
  • uncontrolled diabetes etc
  • (d) Not willing to participate in study

Investigators

Sponsor
King Georges Medical University

Similar Trials